{"title":"Pernix Therapeutics通过收购Cypress Pharmaceutical扩大了仿制药和品牌产品组合","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I11.1840","DOIUrl":null,"url":null,"abstract":"Pernix Therapeutics, a US-based speciality pharmaceutical company primarily focused on the paediatric market, has agreed to acquire the privately held generics developer Cypress Pharmaceutical and its branded pharmaceuticals subsidiary Hawthorn Pharmaceuticals for up to US$101 M in cash and stock. Cypress and Hawthorn are together expected to generate revenues of approximately US$50 M in 2012. The acquisition is Pernix’s second of 2012 after its July purchase of Great Southern Laboratories, a contract manufacturer of OTC and prescription products.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"21 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pernix Therapeutics Expands Generic and Branded Product Portfolios with Cypress Pharmaceutical Acquisition\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2012I11.1840\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Pernix Therapeutics, a US-based speciality pharmaceutical company primarily focused on the paediatric market, has agreed to acquire the privately held generics developer Cypress Pharmaceutical and its branded pharmaceuticals subsidiary Hawthorn Pharmaceuticals for up to US$101 M in cash and stock. Cypress and Hawthorn are together expected to generate revenues of approximately US$50 M in 2012. The acquisition is Pernix’s second of 2012 after its July purchase of Great Southern Laboratories, a contract manufacturer of OTC and prescription products.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"21 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-11-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2012I11.1840\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I11.1840","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Pernix Therapeutics Expands Generic and Branded Product Portfolios with Cypress Pharmaceutical Acquisition
Pernix Therapeutics, a US-based speciality pharmaceutical company primarily focused on the paediatric market, has agreed to acquire the privately held generics developer Cypress Pharmaceutical and its branded pharmaceuticals subsidiary Hawthorn Pharmaceuticals for up to US$101 M in cash and stock. Cypress and Hawthorn are together expected to generate revenues of approximately US$50 M in 2012. The acquisition is Pernix’s second of 2012 after its July purchase of Great Southern Laboratories, a contract manufacturer of OTC and prescription products.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
